Latest Healius (Asx:Hls) News

Healius Limited has landed a significant five-year contract to provide pathology services to the Australian Defence Force, leveraging its national network and digital health solutions.

Healius Limited reported a 5.7% rise in FY25 revenue driven by pathology growth, while underlying EBIT fell 27% impacted by cyclone disruptions and restructuring. The company advances its pathology strategy and cost savings post-Lumus divestment.

Healius reported a 5.7% rise in FY25 revenue with underlying EBIT meeting consensus, buoyed by strong pathology growth and a significant profit from the Lumus Imaging sale. Despite challenges at Agilex Biolabs and a major goodwill impairment, the company targets improved margins by 2027.

Healius Limited has announced a special fully franked dividend of AUD 0.413 per ordinary share, signaling confidence in its financial position despite the ongoing suspension of its Dividend Reinvestment Plan.

Healius Limited has announced a fully franked special dividend of 41.3 cents per share totaling approximately $300 million, alongside a new $300 million three-year syndicated bank facility replacing its previous $680 million arrangement.

Healius Limited has completed the $822 million cash sale of Lumus Imaging to Affinity Equity Partners, setting the stage for a strategic refocus on pathology and a substantial special dividend payout.